H
Helmut Ostermann
Researcher at Ludwig Maximilian University of Munich
Publications - 128
Citations - 4884
Helmut Ostermann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Transplantation & Neutropenia. The author has an hindex of 34, co-authored 123 publications receiving 4257 citations.
Papers
More filters
Journal ArticleDOI
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
Joachim Kienast,Mathias Juers,Christian J. Wiedermann,Johannes N. Hoffmann,Helmut Ostermann,Richard Strauss,Heinz-Otto Keinecke,Brian Warren,Steven M. Opal +8 more
TL;DR: The adapted ISTH DIC score may identify patients with severe sepsis who potentially benefit from high‐dose AT treatment, and may result in a significant mortality reduction.
Journal ArticleDOI
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Ingrid Pabinger,Benjamin Brenner,Uwe Kalina,Sigurd Knaub,A. Nagy,Helmut Ostermann,Beriplex® P +6 more
TL;DR: PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting and more widespread availability of PCC is warranted to ensure its benefits in appropriate patients.
Journal ArticleDOI
Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
H. Link,Angelika Böhme,Oliver A. Cornely,K. Höffken,O. Kellner,W. V. Kern,R. Mahlberg,G. Maschmeyer,M. R. Nowrousian,Helmut Ostermann,Markus Ruhnke,Orhan Sezer,Xaver Schiel,Martin Wilhelm,Holger W. Auner +14 more
TL;DR: In the presence of unexplained fever, fluconazole can be administered at first, but if this fails, amphotericin B (conventional or liposomal), itraconazole, voriconazole or caspofungin should be started.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.
Journal ArticleDOI
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Sabine Mousset,Dieter Buchheidt,Werner J. Heinz,Markus Ruhnke,Oliver A. Cornely,Gerlinde Egerer,William Krüger,Hartmut Link,Silke Neumann,Helmut Ostermann,Jens Panse,Olaf Penack,Christina Rieger,Martin Schmidt-Hieber,Gerda Silling,Thomas Südhoff,Andrew J. Ullmann,Hans-Heinrich Wolf,Georg Maschmeyer,Angelika Böhme +19 more
TL;DR: The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.